S

SlingshotBio

Delivers synthetic cells for drug discovery

Senior HR Generalist

Full-TimeUpdated on 10/23/2026
$85k - $125k
Mid, Senior
Emeryville, CA, USA
In PersonRequires on-site work daily in Emeryville, California.
People & HRHR Generalist & Employee Relations

About the job

Requirements
  • At least 4 years of HR generalist or HR business partner experience.
  • Comfort operating as the sole on-site HR presence, supporting leadership directly day to day, and using a retained fractional HR advisor for complex or higher-stakes matters.
  • Working knowledge of California and federal employment law fundamentals.
  • Experience with applicant tracking system platforms; Greenhouse is preferred.
  • Experience with human resources information systems such as NetSuite SuitePeople HR or equivalent.
  • Strong organizational skills and attention to detail, with the ability to manage multiple day-to-day workstreams.
  • Clear, professional communication skills across all levels of the organization.
Responsibilities
  • Administer day-to-day benefits, including enrollment, employee questions, and qualifying life event processing, in partnership with the benefits broker and carriers.
  • Support annual open enrollment logistics and communications.
  • Maintain accurate employee records in the human resources information system, process employee data changes, and run routine reports for Finance and leadership.
  • Serve as the primary point of contact for employee questions and day-to-day employee relations matters, using the retained fractional HR advisor as a sounding board on complex or high-risk issues.
  • Maintain audit-ready HR documentation and support compliance with California, federal, and applicable employment law requirements.
  • Support investigations, separations, and related documentation.
  • Administer the performance review cycle, including scheduling, tracking completion, and supporting managers with process questions.
  • Maintain the Employee Handbook and HR policies, incorporating updates as directed.
  • Support employee engagement and culture initiatives, including efforts to strengthen the company's presence.
Desired Qualifications
  • Life sciences, biotech, or other regulated-environment experience is a plus.
  • Experience with Greenhouse is preferred.

About the company

Slingshot Biosciences develops and sells synthetic cells for drug discovery, clinical trials, medical testing, and cell therapy manufacturing. These standardized cells are offered on-demand or made-to-order, providing researchers with consistent, controllable materials that replace traditional biological materials to improve data reliability. The company differentiates itself by delivering standardized, customizable, and readily available synthetic cells that reduce variability, with a North American customer focus and emphasis on sustainability. Its goal is to make healthcare more accessible and equitable globally by enabling reliable research and development across biopharma and healthcare.

Company Size

51-200

Company Stage

Series A

Total Funding

$34M

Headquarters

Emeryville, California

Founded

2012

Get referred to SlingshotBio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 ViaComp Ultra XT launch expands workflow coverage and upsell opportunities.
  • February 2026 UK and EU expansion broadens market access beyond North America.
  • Global sales hiring and Cellares partnership strengthen enterprise adoption and distribution.

What critics are saying

  • A CEO transition in September 2026 signals execution pressure after commercial expansion.
  • Pricing at $495 per pack invites commoditization from cheaper control reagents.
  • If flow cytometry incumbents bundle controls, Slingshot's niche platform gets squeezed.

What makes SlingshotBio unique

  • Patented synthetic cell mimics replace donor variability in flow cytometry controls.
  • ViaComp Ultra XT unifies viability dye and antibody unmixing in one vial.
  • Cellares integrated TruCytes into Cell Q, validating industrial automation use.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Retirement Plan
  • Company Equity
  • Performance Bonus
  • Parental Leave
  • Life Insurance
  • Pet Insurance
  • Paid Vacation

Growth & Insights and Company News

6 month growth

0%

1 year growth

-1%

2 year growth

-3%
San Francisco Biotechnology Network
Sep 25th, 2026
Slingshot Biosciences announces leadership transition.

Slingshot Biosciences announces leadership transition. Dr. Nimisha Srivastava Appointed Chief Executive Officer to Lead the Company into Its Next Chapter EMERYVILLE, Calif., Sept. 25, 2026 /PRNewswire/ - Slingshot Biosciences, a leader in precision-engineered cell mimics for flow cytometry, announced that Dr. Nimisha Srivastava has been...

Vialynx Inc
Sep 25th, 2026
Slingshot Biosciences announces leadership transition.

Slingshot Biosciences announces leadership transition. Business · SEP 25, 2026 PR Newswire Dr. Nimisha Srivastava Appointed Chief Executive Officer to Lead the Company into Its Next Chapter EMERYVILLE, Calif., Sept. 25, 2026 /PRNewswire/ - Slin... Dr. Nimisha Srivastava Appointed Chief Executive Officer to Lead the Company into Its Next Chapter EMERYVILLE, Calif., Sept. 25, 2026 /PRNewswire/ - Slingshot Biosciences, a leader in precision-engineered cell mimics for flow cytometry, announced that Dr. Nimisha Srivastava has been appointed Chief Executive Officer, effective September 23, 2026. Dr. Srivastava previously served as the company's Chief Operating Officer. Glenn Bilawsky will transition from his role as Chief Executive Officer. The Board of Directors thanks Glenn for his leadership and contributions to Slingshot. "Nimisha has played a central role in executing our strategy, supporting our teams, advancing our business priorities, and building strong relationships across the organization," said Nicolas Barthelemy, Chairman of the Board of Slingshot Biosciences. "Her deep understanding of our technology, customers, people, and business positions her well to lead Slingshot into its next phase. The Board has full confidence in her leadership and looks forward to supporting her as we continue to build the company." As CEO, Dr. Srivastava will focus on accelerating commercial growth, advancing new product development, strengthening customer relationships, and executing against the company's strategic priorities. "I am honored and humbled to take on the role of CEO, and I am grateful to the Board for its confidence in me," said Dr. Nimisha Srivastava, CEO of Slingshot Biosciences. "While this is an important transition for the company, our focus remains unchanged: building the business, bringing innovative products to market, growing and retaining our customer base, and delivering meaningful results for our customers and stakeholders. I know this technology, our people, and the work ahead of us, and I am excited about what we can accomplish together." Dr. Srivastava brings extensive experience in scaling disruptive technologies, developing automated workflows, and building high-throughput manufacturing processes. Prior to joining Slingshot, she was a member of the founding engineering team at Twist Bioscience, where she led the scale-up of laboratory processes, automated workflows, and high-throughput synthetic DNA and RNA production. Under Dr. Srivastava's leadership, Slingshot will continue advancing its mission to replace traditional biological reference materials with scalable, customizable, and cost-effective cell mimic controls. The company will continue to develop and commercialize its portfolio of precision-engineered cell mimics across flow cytometry, cell therapy, drug development, diagnostics, and life sciences research. The leadership transition is focused on continuity, focus, and execution, with Slingshot's core strategy and priorities remaining firmly in place. About Slingshot Biosciences Slingshot Bio invented precision-engineered synthetic cell mimics for flow cytometry controls: manufactured, shelf-stable particles that reproduce the scatter and biomarker signatures of real cells, with the one thing biology can't guarantee: reproducibility. Founded in 2012 and headquartered in Emeryville, California, with thousands of flow cytometrists across the globe using its cell mimic products, Slingshot replaces the variable, perishable, and subpar reference materials that inhibit flow cytometry analysis with products manufactured under the highest quality standards and delivering unmatched performance. Cell therapy, drug development, diagnostics, and instrument manufacturers worldwide have adopted Slingshot Bio flow cytometry controls. Learn more at slingshotbio.com. Media Contact SOURCE Slingshot Biosciences Published by News Desk · WeeklyReviewer The WeeklyReviewer news desk monitors breaking developments around the clock - sourcing, verifying, and publishing real-time industry news across business, technology, politics, science, sports, and world affairs. Every story that comes through the Live Wire is reviewed for accuracy before publication, keeping our readers ahead of the curve without the noise.

GenomeWeb
Sep 25th, 2026
People in the news.

People in the news. GenomeWeb tracks the career moves of prominent people in the fields of genetics, genomics, diagnostics, and precision medicine. People in the news for the week of Sept. 21, 2026: Nimisha Srivastava, Glenn Bilawsky, Doug White, Vijay Singh, Carl Raimond, Michael Chen, David Horn, Charles Endweiss September 25, 2026 09:32 AM EDT Nimisha Srivastava has been promoted to CEO of Slingshot Biosciences, replacing Glenn Bilawsky. September 25, 2026 06:04 AM EDT Astek Diagnostics has appointed Doug White the executive chairman of its board. September 24, 2026 10:10 AM EDT Vijay Singh has been appointed as CSO of the life sciences tools division of Longhorn Vaccines and Diagnostics. September 22, 2026 06:25 PM EDT Carl Raimond has been appointed as CEO of Nuclera. September 22, 2026 10:13 AM EDT Seer announced the firm's President, CFO, and Treasurer David Horn is leaving Seer. Charles Endweiss will take over as treasurer, principal financial officer, and principal accounting officer. September 21, 2026 09:16 AM EDT Joel Fellis is leaving Illumina, where he has been serving as VP of strategic innovation. September 17, 2026 05:21 PM EDT Astrin Biosciences has appointed Tanya Gupta as medical director. September 17, 2026 03:54 PM EDT VedaBio has appointed Valerie Dixon as the first independent member of its board of directors. September 17, 2026 03:37 PM EDT Josh Denny will step down as CEO of the National Institutes of Health's All of Us Research Program on Oct. 31, after almost seven years, to take up a leadership position at the University of Chicago. September 16, 2026 03:31 PM EDT

PR Newswire
Aug 17th, 2026
Slingshot Bio launches ViaComp Ultra Amine for multiparameter flow cytometry compensation

Slingshot Bio has launched ViaComp Ultra Amine, a compensation control for amine-reactive viability dyes and antibody panels in multiparameter flow cytometry. The cell mimic control is designed to support spectral unmixing and compensation across complex workflows. The product captures amine-reactive viability dyes and fluorophore-conjugated antibodies from multiple host species — including mouse, rat, hamster, rabbit, and human — in a single reagent. Each vial contains pre-mixed positive and negative control particles that generate well-separated peaks with the fluorescence spectrum being tested. The ready-to-use liquid format eliminates preparation requirements associated with traditional cell-based controls. ViaComp Ultra Amine is available through Slingshot Bio's commercial catalogue and is manufactured under ISO 9001 quality management standards. Slingshot Bio is based in Emeryville, California, and develops cell mimic controls for flow cytometry using semiconductor manufacturing techniques.

PR Newswire
Mar 5th, 2026
Slingshot Biosciences appoints Jim Snook as senior VP of global sales

Slingshot Biosciences has appointed Jim Snook as Senior Vice President, Global Sales. Snook brings over 20 years of executive sales leadership experience in life sciences, most recently serving as Vice President, Commercial at Bio-Techne's Protein Sciences unit, where he led sales transformation efforts. Previously, Snook led Miltenyi Biotec's Americas commercial team, growing it into a market leader in cell and gene therapy manufacturing solutions. At Slingshot, he will oversee the global sales organisation, including business development, inside sales, distribution and field application scientists. The appointment comes as the company experiences rapid adoption of its synthetic cell mimic platform among pharmaceutical companies, biotech firms, clinical diagnostics laboratories and academic institutions. Slingshot Biosciences develops synthetic controls for flow cytometry that provide improved reproducibility and stability compared to traditional biological controls.